Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thymalfasin - SciClone Pharmaceuticals

Next Previous
Search
Drug Profile

Thymalfasin - SciClone Pharmaceuticals

Alternative Names: Thymosin-α-1; Tα 1; Zadaxin

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas at Austin
  • Developer SciClone Pharmaceuticals; sigma-tau SpA
  • Class Adjuvants; Anti-infectives; Antineoplastics; Antivirals; Oligopeptides; Thymus hormones
  • Mechanism of Action Th1 cell stimulants; Th2 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Hepatitis B; Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Marketed Cancer; Hepatitis B; Hepatitis C
  • Phase III Sepsis
  • No development reported COVID 2019 infections
  • Discontinued Liver cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Combination therapy, In volunteers) in China (Parenteral)
  • 26 Apr 2021 Clinical trials in COVID-2019 infections (Combination therapy) in China (Parenteral)
  • 08 Apr 2021 Discontinued - Phase-II for Liver cancer in USA (Intrahepatic)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top